Synvero Health · US health-tech
Synvero Health develops AI-powered digital adherence, monitoring and coaching solutions that make inhaled drug delivery more efficient and improve clinical outcomes for patients with asthma and COPD.
45M
US patients suffer from asthma and COPD
US · EU · Asia
patents protecting our AI and technology
7
studies and pilots
The problem
Inhaled therapies treat asthma and COPD, yet the devices have changed little over the years. Handling errors mean inadequate drug delivery, poor symptom control, ER visits and avoidable costs.
Up to 90%
of inhaler treatments are used incorrectly
80M
people with respiratory disease in the US and EU
50%
of inhalations deliver no dose
Our solution: Kata
AI-driven sound and video technology coaches patients in real time on their inhalation errors. Kata is software only, so it scales across health systems without new hardware.
01
Reminds patients to take their therapy and trains correct inhaler technique.
02
Monitors inhaler technique and coaches patients on errors in real time.
03
Remote patient intervention at the touch of a smartphone.
Clinically validated
>95%
of available inhaler devices covered
Up to 100%
reduction in device-handling errors
7
trials and usability pilots with more than 300 patients
2,500
active users
About Synvero
Synvero Health is a US health-tech company developing AI-powered digital adherence, monitoring and coaching solutions for patients with asthma and COPD. Our founders bring decades of experience in respiratory medicine, medical devices and market access.
Work with us
We are preparing our US market entry through commercial partnership with payers, health networks and providers who treat patients with respiratory diseases. Health care professionals, payers and investors: we’d like to engage with you.
